JOP20230298A1 - طرق علاج الاضطرابات المرتبطة بالميتوكوندريا - Google Patents

طرق علاج الاضطرابات المرتبطة بالميتوكوندريا

Info

Publication number
JOP20230298A1
JOP20230298A1 JOJO/P/2023/0298A JOP20230298A JOP20230298A1 JO P20230298 A1 JOP20230298 A1 JO P20230298A1 JO P20230298 A JOP20230298 A JO P20230298A JO P20230298 A1 JOP20230298 A1 JO P20230298A1
Authority
JO
Jordan
Prior art keywords
treatment
treatment methods
mitochondrial disorders
imidazole
nitro
Prior art date
Application number
JOJO/P/2023/0298A
Other languages
Arabic (ar)
English (en)
Inventor
Jorkasky Diane
Khan Shaharyar
Original Assignee
Rivus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivus Pharmaceuticals Inc filed Critical Rivus Pharmaceuticals Inc
Publication of JOP20230298A1 publication Critical patent/JOP20230298A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JOJO/P/2023/0298A 2021-05-20 2023-11-19 طرق علاج الاضطرابات المرتبطة بالميتوكوندريا JOP20230298A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163191321P 2021-05-20 2021-05-20
US202163222841P 2021-07-16 2021-07-16
US202263307515P 2022-02-07 2022-02-07
PCT/US2022/029992 WO2022246039A1 (en) 2021-05-20 2022-05-19 Methods of treating mitochondria-related disorders

Publications (1)

Publication Number Publication Date
JOP20230298A1 true JOP20230298A1 (ar) 2023-11-19

Family

ID=82020295

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0298A JOP20230298A1 (ar) 2021-05-20 2023-11-19 طرق علاج الاضطرابات المرتبطة بالميتوكوندريا

Country Status (14)

Country Link
US (1) US20250177353A1 (https=)
EP (1) EP4340829A1 (https=)
JP (1) JP2024521709A (https=)
KR (1) KR20240021827A (https=)
AU (1) AU2022275935A1 (https=)
BR (1) BR112023024146A2 (https=)
CA (1) CA3219548A1 (https=)
CL (1) CL2023003441A1 (https=)
GE (1) GEAP202416398A (https=)
IL (1) IL308669A (https=)
JO (1) JOP20230298A1 (https=)
MX (1) MX2023013688A (https=)
TW (1) TW202313010A (https=)
WO (1) WO2022246039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150759A1 (en) * 2022-02-07 2023-08-10 Rivus Pharmaceuticals, Inc. Methods of weight loss in a subject with elevated hba1c
TW202515545A (zh) * 2023-08-10 2025-04-16 大陸商深圳君聖泰生物技術有限公司 ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Also Published As

Publication number Publication date
EP4340829A1 (en) 2024-03-27
KR20240021827A (ko) 2024-02-19
JP2024521709A (ja) 2024-06-04
CL2023003441A1 (es) 2024-05-10
US20250177353A1 (en) 2025-06-05
TW202313010A (zh) 2023-04-01
WO2022246039A1 (en) 2022-11-24
AU2022275935A1 (en) 2023-12-07
BR112023024146A2 (pt) 2024-01-30
CA3219548A1 (en) 2022-11-24
MX2023013688A (es) 2024-02-27
GEAP202416398A (en) 2024-01-25
IL308669A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
JOP20230298A1 (ar) طرق علاج الاضطرابات المرتبطة بالميتوكوندريا
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
AR072805A1 (es) Composiciones intranasales formas galenicas y metodos de tratamiento.
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
JP2019529541A5 (https=)
FI3672631T3 (fi) Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia
RU2019110150A (ru) Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
BR112023017999A2 (pt) Obicetrapibe para tratamento de demências
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
BR112022008095A2 (pt) Métodos e composições para o tratamento da síndrome de rett
CO2025007626A2 (es) Composiciones farmacéuticas para administración ocular
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
EA202190614A1 (ru) Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря
WO2021202546A8 (en) Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death
RU2007138263A (ru) Противовоспалительные соединения
AR109760A1 (es) Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson
Bhangire et al. A single case study of role of Shodhan and Shaman Karma in the management of Vicharchika (Eczema)
RU2295349C2 (ru) Способ лечения остеоартроза коленных суставов с использованием внутрисуставного введения препарата "хондролон"
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
ZA202308870B (en) Cyclopropane analogues of n-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide and related compounds